Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.

The insulinotropic gut hormone gastric inhibitory polypeptide (GIP) has been demonstrated to inhibit gastric acid secretion and was proposed to possess "enterogastrone" activity. GIP effects on gastric emptying have not yet been studied. Fifteen healthy male volunteers (23.9 +/- 3.3 yr, body mass index 23.7 +/- 2.3 kg/m(2)) were studied with the intravenous infusion of GIP (2 pmol.kg(-1).min(-1)) or placebo, each administered to the volunteers on separate occasions from -30 to 360 min in the fasting state. At 0 min, a solid test meal (250 kcal containing [(13)C]sodium octanoate) was served. Gastric emptying was calculated from the (13)CO(2) exhalation rates in breath samples collected over 360 min. Venous blood was drawn in 30-min intervals for the determination of glucose, insulin, C-peptide, and GIP (total and intact). Statistical calculations were made by use of repeated-measures ANOVA and one-way ANOVA. During the infusion, GIP rose to steady-state concentrations of 159 +/- 15 pmol/l for total and 34 +/- 4 pmol/l for intact GIP (P < 0.0001). Meal ingestion further increased GIP concentrations in both groups, reaching peak levels of 265 +/- 20 and 82 +/- 9 pmol/l for total and 67 +/- 7 and 31 +/- 9 pmol/l for intact GIP during the administration of GIP and placebo, respectively (P < 0.0001). There were no differences in glucose, insulin, and C-peptide between the experiments with the infusion of GIP or placebo. Gastric half-emptying times were 120 +/- 9 and 120 +/- 18 min (P = 1.0, with GIP and placebo, respectively). The time pattern of gastric emptying was similar in the two groups (P = 0.98). Endogenous GIP secretion, as derived from the incremental area under the curve of plasma GIP concentrations in the placebo experiments, did not correlate to gastric half-emptying times (r(2) = 0.15, P = 0.15 for intact GIP; r(2) = 0.21, P = 0.086 for total GIP). We conclude that gastric emptying does not appear to be influenced by GIP. The secretion of GIP after meal ingestion is not suppressed by its exogenous administration. The lack of effect of GIP on gastric emptying underlines the differences between GIP and the second incretin glucagon-like peptide 1.

[1]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[2]  A. Shulkes,et al.  Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man , 1980, Digestive Diseases and Sciences.

[3]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[4]  J. Holst,et al.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.

[5]  J. Holst,et al.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  J. Holst,et al.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.

[7]  J. Holst,et al.  The reduction in hepatic insulin clearance after oral glucose is not mediated by Gastric inhibitory polypeptide (GIP) , 2003, Regulatory Peptides.

[8]  M. Horowitz,et al.  Gastric emptying in diabetes: clinical significance and treatment , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[9]  J. Holst,et al.  Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. , 2001, Diabetes.

[10]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[11]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[12]  J. Habener,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist* , 2000 .

[13]  M. Boylan,et al.  Glucose-Dependent Insulinotropic Polypeptide (GIP) , 1999 .

[14]  J. Holst,et al.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans , 1997 .

[15]  T. Usdin,et al.  Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. , 1996, The Journal of clinical investigation.

[16]  B. Göke,et al.  Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.

[17]  B. Braden,et al.  The [13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. , 1995, Gastroenterology.

[18]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[19]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[20]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[21]  M. Nauck,et al.  Gut hormones and diabetes mellitus. , 1992, Diabetes/metabolism reviews.

[22]  T. Krarup.  Immunoreactive gastric inhibitory polypeptide. , 1988, Endocrine reviews.

[23]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[24]  W. Creutzfeldt,et al.  Role of GIP and insulin in glucose-induced changes in intestinal motility patterns. , 1987, The American journal of physiology.

[25]  B. Draznin,et al.  Feedback inhibition of insulin on insulin secretion in isolated pancreatic islets. , 1986, Endocrinology.

[26]  M. Wolfe,et al.  Inhibition of gastrin release by gastric inhibitory peptide mediated by somatostatin. , 1986, The American journal of physiology.

[27]  M. Wolfe,et al.  Effects of antibodies to gastric inhibitory peptide on gastric acid secretion and gastrin release in the dog. , 1983, Gastroenterology.

[28]  H. T. Debas,et al.  Gastric inhibitory polypeptide (GIP) is not the primary mediator of the enterogastrone action of fat in the dog. , 1980, Gastroenterology.

[29]  N. I. Ramus,et al.  Suppression of Gastrin Release and Gastric Secretion by Gastric Inhibitory Polypeptide (GIP) and Vasoactive Intestinal Polypeptide (VIP) , 1976, Annals of surgery.

[30]  J. Brown,et al.  A gastric inhibitory polypeptide. II. The complete amino acid sequence. , 1971, Canadian journal of biochemistry.

[31]  R. Harris,et al.  Reaction of trans-Chlorocarbonylbis(triphenylphosphine) Iridium(I) and its Analogues with Oxidizing Metal Salts , 1971 .

[32]  J. Brown,et al.  Further purification of a polypeptide demonstrating enterogastrone activity , 1970, The Journal of physiology.

[33]  D. Brömster,et al.  Measurement of gastric emptying-rate. , 1966, Lancet.

[34]  R. K. Lim,et al.  Demonstration of the Humoral Agent in Fat Inhibition of Gastric Secretion. , 1930 .